Dr. Reddy's revealed that three facilities that have been sanctioned by the FDA will be re-inspected by the agency in the current quarter, livemint.com reported.
"All the commitments as part of warning letter response have been completed," the company said.
The sanctions have had a material impact on revenue for the drugmaker, which generated about half of its revenue in the US for the year ended March 2016.
Dr. Reddy's currently has 83 products awaiting FDA clearance.
Separately, the drugmaker provided an update on its growth strategy, including the planned launch of complex generics, speciality brands and over-the-counter brands in the US and expansion into new markets such as Japan, China and Columbia.
To read more NewsPoints articles, click here.